In response to the National Institute of Health and Clinical Excellence's decision not to approve omalizumab (xolair) for use in children aged six to 11, Asthma UK expressed its disappointment as studies show the medication to significantly reduce hospital admissions.
The body, which is dedicated to helping the 5.4 million asthma sufferers in the UK, told medical bracelet wearers that research indicated the drug may help with the condition and 'end their dependency on the NHS'.
Novartis, which manufactures xolair, stated that the drug could help 300 children in the age group who have severe symptoms of the chronic inflammatory disease.
Asthma UK said that this medication remained a better alternative than needing to give oral corticosteroids, which is thought to increase the risk of potential side effects such as growth retardation, diabetes and even heart failure.
The body, which is dedicated to helping the 5.4 million asthma sufferers in the UK, told medical bracelet wearers that research indicated the drug may help with the condition and 'end their dependency on the NHS'.
Novartis, which manufactures xolair, stated that the drug could help 300 children in the age group who have severe symptoms of the chronic inflammatory disease.
Asthma UK said that this medication remained a better alternative than needing to give oral corticosteroids, which is thought to increase the risk of potential side effects such as growth retardation, diabetes and even heart failure.
0 comments:
Post a Comment